BioCentury
ARTICLE | Company News

Vaxxas, Merck in vaccine deal

October 9, 2012 12:38 AM UTC

Vaxxas Pty. Ltd. (Sydney, Australia) granted Merck & Co. Inc. (NYSE:MRK) exclusive, worldwide rights to develop and commercialize a vaccine using Vaxxas' needle-free Nanopatch vaccine delivery technology. Merck also has an option to license the technology for use with two additional undisclosed vaccine candidates. Vaxxas will receive an upfront payment and research funding. Vaxxas is eligible for milestones, plus royalties. The companies declined to disclose details. ...